Current calls, week 47, 2023
Tips from KI Grants Office about current calls.
Swedish and Nordic calls
Forsknings- och resestipendier - Svensk förening för sömnforskning och sömnmedicin (SFSS)
Forskningsstipendier kan sökas för kostnader i samband med forskningsprojekt med inriktning mot grundforskning, samhällsvetenskaplig forskning eller klinisk forskning inom sömn och dygnsrytm. Resestipendier kan sökas för kostnader (resa, logi, kongressavgift) i samband med kongressdeltagande, kurs eller studiebesök i forskargrupp eller motsvarande. Resestipendier är 5 000 kr för resor inom Europa och 10 000 kr för resor utanför Europa. Totalt har avsatts 100 000 kr för att fördelas som stipendier. Ansökan skall lämnas in skriftligen per E-post till föreningens stipendieansvariga.
Closing date: December 30, 2023
Travel grants - Swedish Childhood Cancer Foundation
Travel grants enable researchers to participate in international conferences or congresses in the field of paediatric oncology. Medical doctors, researchers, counsellors, psychologists and nurses may apply. The applicant should be active in the field of childhood cancer. Grants are worth up to SEK 9,000 for travel within the Nordic countries, up to SEK 11,000 for travel in Europe and up to SEK 20,000 for travel outside Europe. The grants are generally intended to fully or partly cover low-price return tickets, hotel costs, registration fee, and return transfer tickets.
Closing date: January 15, 2024
Forsknings- och innovationsprojekt – Vinnova
Stödjer nyskapande, mindre forsknings- och innovationsprojekt som behandlar en radikal och innovativ frågeställning. Det innebär att nyhetsvärdet och osäkerhetsfaktorn kan vara högre än i mer traditionella projekt. Projekt som syftar till att verifiera, bekräfta eller avfärda nydanande innovativa uppslag för ett mer omfattande projekt. Kan sökas i första hand av tillverkare, leverantörer och användare av biobaserade material, produkter och tjänster, men även universitet, högskolor, forskningsinstitut och andra relevanta aktörer. Finansieras med högst 500 000 kronor för ett projekt. Projekt ska samfinansieras av medverkande företag med motsvarande summa som det sökta bidraget.
Closing date: March 5, 2024
Märta Lundqvists stiftelse år 2023/2024
Stiftelsens övergripande syfte är att främja forskningen om den mänskliga hjärnan vid svenska universitet. Särskilt prioriteras patientrelaterad och kliniskt fokuserad forskning. Stiftelsen har också som mål att stimulera yngre forskare.
Forskningsprogrammet ska innehålla tydliga mål så att resultatet kan utvärderas. Storleken på utdelningsbara medel uppgår till 3 160 000 kronor.
Closing date: January 15, 2024
The Fulbright Arctic Initiative (FAI)
Den fjärde fasen av Fulbright Arctic Initiative (FAI IV) är nu öppen för kandidater från Sverige, Finland, Island, Norge, Ryssland, Kanada, Danmark och USA. Detta 18-månadersprogram börjar i september 2024 och kommer att ta itu med viktiga forsknings- och policyfrågor som i slutänden relaterar till främjandet av arktisk säkerhet.
Forskningsfrågor som förknippas med gemensamma arktiska utmaningar och möjligheter kan bidra till att Arktis utgör en trygg, hälsosam, välmående och hållbar plats att leva och verka på idag så väl som imorgon. Stipendiesumman är på 40 000 USD. Ett första informationswebbinarium kommer att hållas den 6 december 2023
Closing date: March 1, 2024
European calls
IFCAH-ESPE Grants - European Society for Paediatric Endocrinology (ESPE), INT
IFCAH (International Fund Congenital Adrenal Hyperplasia) is a private fundraising organisation aiming to promote academic research on Congenital Adrenal Hyperplasia. This aims to promote research on Congenital Adrenal Hyperplasia (CAH).
Specific goals
Increasing knowledge on pathophysiology of CAH.
The projects should be relevant to CAH. The projects could include research on adrenal development,
differentiation and homeostasis, but in any case, relevance to CAH should be emphasized. Research on adrenal tumours and cancer is excluded from this call.
Prevention, diagnostic and treatment of natural or iatrogenic complications
Impact on foetal development, growth, puberty, effects on metabolic and cardiovascular systems, male and female fertility, bone density, immunity, infection, neuro cognition…
Proposition of new therapeutic targets and protocols
Pharmacotherapy, Development of gene or/and cellular therapy models.
The grant is worth up to 150’000 EUR. No INDI coverage.
Closing date: January 15, 2024 (LOI), April 2024: Full application due date (for accepted LOIs)
EFSD/Lilly Young Investigator Research Award Programme
The objective of the EFSD/Lilly Young Investigator Research Awards is to encourage innovative research in the fields of diabetes and its complications, and to promote excellence in medical education. Applicants should have demonstrated their ability in the field of diabetes research.
The grant is worth 50,000EUR.
Closing date: 15 February 2024
Research fellowship - United European Gastroenterology Federation (UEGF), INT
This fellowship enables a researcher to spend 12 months working with a renowned European principal investigator on an extensive research project. The main purpose of this fellowship is to support the development of a basic or clinical research project and give the fellows the chance to improve their scientific skills. The fellowships are highly recommended for young researchers who are not in a position to develop their ideas at their current place of work.
Centers must be located in Europe or the Mediterranean area (countries that are bordering the Mediterranean Sea), but not in the fellow’s current country of residence.
The grant is worth € 50,000.
Closing date: March 1, 2024
US calls
Federal Funding
NIH - Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
Funding Opportunity ID: PAR-22-062
Upcoming deadlines: Standard dates apply.
Abstract: The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter their effectiveness and thus those parameters should be rigorously addressed in the application.
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
Funding Opportunity ID: PAR-23-208
Upcoming deadlines: Standard dates apply.
Abstract: The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R21 mechanism, while the companion PAR-23-207 uses the R01 grant mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.
Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)
Funding Opportunity ID: PAR-23-083
Upcoming deadlines: Full application – 20th February, 2024; 18th June, 2024; 18th October, 2024
Abstract: The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.
Adolescent Overdose Prevention and SUD Treatment Initiative (R21 - Clinical Trial Not Allowed)
Funding Opportunity ID: RFA-DA-25-030
Upcoming deadlines: Full application – 13th March, 2024
Abstract: This notice of funding opportunity (NOFO) encourages exploratory and developmental research to better understand adolescent illicit fentanyl use and overdose patterns among adolescents at high risk for overdose (i.e., intentional, unintentional, fatal, and/or non-fatal). Research studies should identify targets for overdose prevention and substance use disorder (SUD) treatment and recovery. Research studies may use a variety of approaches (e.g., leveraging existing data sources, survey research, social network analysis, development of new methods, feasibility research). Outcomes of interest include, but are not limited to, prevalence of overdose and reduction in substance use, particularly fentanyl use or use of substances that are commonly laced with fentanyl; unintentional use/overdose, use/overdose by risk group, stigma, family and environmental risk and protective factors, treatment engagement, adolescents' perceptions of substance use, and optimistic bias. Research studies involving services delivery or interventions are encouraged to consider the companion NOFO, RFA-DA-25-031, Adolescent Overdose Prevention and SUD Treatment Initiative (R34 - Clinical Trial Optional).
Foundation
National Psoriasis Foundation (NPF), US – Various research grants
Upcoming deadlines: Full application – 1st February, 2024
Amount: From $50,000 to $200,000. 1-3 years. No indirect cost coverage.
Eligibility: Applicants must hold an M.D., Ph.D., or equivalent academic degree. Eligibility will vary between grants, see specific funding call for details.
Abstract: Each year, the National Psoriasis Foundation (NPF) awards grants and fellowships that fund work focused on the treatment, prevention, and cure of psoriasis, psoriatic arthritis (PsA), and comorbidities. NPF has invested over $30 million in grants and fellowships focused on psoriatic disease and related comorbidities. As a primary goal in the current strategic plan, leading transformational research in psoriatic disease, NPF chooses research projects not only for their potential to yield information that may help treat psoriatic disease, but also to answer basic questions about the underlying disease mechanisms, comorbidities, and public health. Applications undergo a rigorous scientific peer review by a panel of experts.
American Brain Tumor Association (ABTA), US – Discovery Grant
Upcoming deadlines: LOI – December 13th, 2023: Full application – 27th March, 2024
Amount: Up to $50,000 for up to one year. No indirect cost coverage.
Eligibility: Must have a doctoral degree, including MD, PhD, DrPH, DO, or equivalent at the time of Letter of Intent (LOI) submission. At the start of the grant term, applicants must hold a full-time faculty position and cannot have held a full-time faculty appointment before September 1, 2014.
Abstract: The American Brain Tumor Association seeks applications from faculty who propose highrisk/high-impact projects with the potential to change current diagnostic or treatment paradigms for adult and pediatric brain tumor care. We seek projects focused on all brain tumor types, benign or malignant, primary, or secondary (metastatic), and that will have an impact on pediatric, adult, or both populations.
Amyotrophic Lateral Sclerosis Association, US – The Lawrence and Isabel Barnett Drug Development Program
Upcoming deadlines: LOI – December 13th, 2023: Full application – 27th March, 2024
Amount: Up to $500,000 for up to 2 years. Up to 10% indirect cost coverage.
Eligibility: Individuals with the skills, knowledge, and resources necessary to carry out the proposed research may apply as a PI. Postdoctoral fellows are not eligible to apply as a PI.
Abstract: There is an urgent need for new and improved therapies for ALS, as there is still no cure. The Lawrence and Isabel Barnett Drug Development Program seeks to accelerate the availability of new, effective ALS treatments by supporting the preclinical assessment of novel therapies or repositioned treatment approaches in preparation for clinical testing. Both novel programs and repurposing of approved or clinically safe therapies from other disease indications are appropriate for this funding opportunity. We are especially interested in: In vivo efficacy testing of therapeutic candidates (pharmacological treatments, biological therapies, or gene therapies) in models of ALS. Studies focused on pharmacokinetics, pharmacodynamics, preclinical toxicology/safety (ADME/Tox), dose-range finding, and target engagement. Other Investigational New Drug (IND)-enabling studies.